{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:59:25Z","timestamp":1763755165711,"version":"3.45.0"},"reference-count":48,"publisher":"Oncology Nursing Society (ONS)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Journal of Oncology Nursing"],"published-print":{"date-parts":[[2006,8,1]]},"DOI":"10.1188\/06.cjon.514-520","type":"journal-article","created":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T10:42:38Z","timestamp":1187865758000},"page":"514-520","source":"Crossref","is-referenced-by-count":5,"title":["Advances in Oral Therapy in the Treatment of Multiple Myeloma"],"prefix":"10.1188","volume":"10","author":[{"given":"Deborah S.","family":"Doss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2007,1,2]]},"reference":[{"key":"E00001","doi-asserted-by":"crossref","unstructured":"Alexanian, R., Barlogie, B., & Dixon, D. (1986). High-dose gluco-corticoid treatment of resistant myeloma. <i>Annals of Internal Medicine, 105<\/i>, 8-11.","DOI":"10.7326\/0003-4819-105-1-8"},{"key":"E00002","doi-asserted-by":"crossref","unstructured":"Alexanian, R., Barlogie, B., & Tucker, S. (1990). VAD-based regimens as primary treatment for multiple myeloma. <i>American Journal of Hematology, 33<\/i>, 86-89.","DOI":"10.1002\/ajh.2830330203"},{"key":"E00003","doi-asserted-by":"crossref","unstructured":"Alexanian, R., Dimopoulos, M.A., Delasalle, K., & Barlogie, B. (1992). Primary dexamethasone treatment of multiple myeloma. <i>Blood, 80<\/i>, 887-890.","DOI":"10.1182\/blood.V80.4.887.887"},{"key":"E00004","doi-asserted-by":"crossref","unstructured":"Alexanian, R., Weber, D., Giralt, S., & Delasalle, K. (2002). Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. <i>Annals of Oncology, 13<\/i>, 1116-1119.","DOI":"10.1093\/annonc\/mdf188"},{"key":"E00005","unstructured":"American Cancer Society. (2005). <i>Cancer facts and figures 2005.<\/i> Retrieved June 14, 2005, from <a target=\"_blank\" href='http:\/\/www.cancer.org\/downloads\/STT\/CAFF2005f4PWSecured.pdf'>http:\/\/www.cancer.org\/downloads\/STT\/CAFF2005f4PWSecured.pdf<\/a>"},{"key":"E00006","doi-asserted-by":"crossref","unstructured":"Anagnostopoulos, A., Weber, D., Rankin, K., Delasalle, K., & Alexanian, R. (2003). Thalidomide and dexamethasone for resistant multiple myeloma. <i>British Journal of Haematology, 121<\/i>, 768-771.","DOI":"10.1046\/j.1365-2141.2003.04345.x"},{"key":"E00007","doi-asserted-by":"crossref","unstructured":"Anderson, K.C. (2003). The role of immunomodulatory drugs in multiple myeloma. <i>Seminars in Hematology, 40<\/i>(4, Suppl. 4), 23-32.","DOI":"10.1053\/j.seminhematol.2003.09.010"},{"key":"E00008","doi-asserted-by":"crossref","unstructured":"Barlogie, B., Desikan, R., Eddlemon, P., Spencer, T., Zeldis, J., Munshi, N., et al. (2001). Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. <i>Blood, 98<\/i>, 492-494.","DOI":"10.1182\/blood.V98.2.492"},{"key":"E00009","doi-asserted-by":"crossref","unstructured":"Bartlett, J.B., Dredge, K., & Dalgleish, A.G. (2004). The evolution of thalidomide and its IMiD derivatives as anticancer agents. <i>Nature Reviews. Cancer, 4<\/i>, 314-322.","DOI":"10.1038\/nrc1323"},{"key":"E00010","doi-asserted-by":"crossref","unstructured":"Bernardeschi, P., Dentico, P., Rossi, S., Fiorentini, G., Giustarini, G., Montenora, I., et al. (2004). Chemoresistant myeloma: Phase II clinical study with low-dose thalidomide plus high-dose dexamethasone. <i>Journal of Chemotherapy, 16<\/i>(Suppl. 5), 90-93.","DOI":"10.1080\/1120009X.2004.11782395"},{"key":"E00011","unstructured":"Cavo, M., Zamagni, E., Tosi, P., Cellini, C., Cangini, D., Tacchetti, P., et al. (2004). First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. <i>Haematologica, 89<\/i>, 826-831."},{"key":"E00012","doi-asserted-by":"crossref","unstructured":"Cavo, M., Zamagni, E., Tosi, P., Tacchetti, P., Cellini, C., Cangini, D., et al. (2005). Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. <i>Blood, 106<\/i>, 35-39.","DOI":"10.1182\/blood-2005-02-0522"},{"key":"E00013","unstructured":"Celgene Corporation. (2005, May 15). Revlimid\u00ae (lenalidomide) significantly delays time to disease progression in previously treated multiple myeloma patients. Retrieved June 28, 2005, from <a target=\"_blank\" href='http:\/\/ir.celgene.com\/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=709974&highlight='>http:\/\/ir.celgene.com\/phoenix.zhtml?c=111960&p=irol-newsArticle&ID=709974&highlight=<\/a>"},{"key":"E00014","doi-asserted-by":"crossref","unstructured":"D'Amato, R.J., Loughnan, M.S., Flynn, E., & Folkman, J. (1994). Thalidomide is an inhibitor of angiogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America, 91<\/i>, 4082-4085.","DOI":"10.1073\/pnas.91.9.4082"},{"key":"E00015","doi-asserted-by":"crossref","unstructured":"Friedenberg, W.R., Kyle, R.A., Knospe, W.H., Bennett, J.M., Tsiatis, A.A., & Oken, M.M. (1991). High-dose dexamethasone for refractory or relapsing multiple myeloma. <i>American Journal of Hematology, 36<\/i>, 171-175.","DOI":"10.1002\/ajh.2830360303"},{"key":"E00016","unstructured":"Ghobrial, I.M., & Rajkumar, S.V. (2003). Management of thalidomide toxicity. <i>Journal of Supportive Oncology, 1<\/i>, 194-205."},{"key":"E00017","doi-asserted-by":"crossref","unstructured":"Harousseau, J.L., Shaughnessy, J., Jr., & Richardson, P. (2004). Multiple myeloma. <i>Hematology\/American Society of Hematology Education Program Book, 1<\/i>, 237-256","DOI":"10.1182\/asheducation-2004.1.237"},{"key":"E00018","doi-asserted-by":"crossref","unstructured":"Hideshima, T., & Anderson, K.C. (2002). Molecular mechanisms of novel therapeutic approaches for multiple myeloma. <i>Nature Reviews. Cancer, 2<\/i>, 927-937.","DOI":"10.1038\/nrc952"},{"key":"E00019","unstructured":"Hus, M., Dmoszynska, A., Soroka-Wojtaszko, M., Jawniak, D., Legiec, W., Ciepnuch, H., et al. (2001). Thalidomide treatment of resistant or relapsed multiple myeloma patients. <i>Haematologica, 86<\/i>, 404-408."},{"key":"E00020","doi-asserted-by":"crossref","unstructured":"Kumar, S., Gertz, M.A., Dispenzieri, A., Lacy, M.Q., Geyer, S.M., Iturria, N.L., et al. (2003). Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. <i>Mayo Clinic Proceedings, 78<\/i>, 34-39.","DOI":"10.4065\/78.1.34"},{"key":"E00021","doi-asserted-by":"crossref","unstructured":"Kyle, R.A., & Rajkumar, S.V. (2004). Multiple myeloma. <i>New England Journal of Medicine, 351<\/i>, 1860-1873.","DOI":"10.1056\/NEJMra041875"},{"key":"E00022","doi-asserted-by":"crossref","unstructured":"Lentzsch, S., LeBlanc, R., Podar, K., Davies, F., Lin, B., Hideshima, T., et al. (2003). Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. <i>Leukemia, 17<\/i>, 41-44.","DOI":"10.1038\/sj.leu.2402745"},{"key":"E00023","doi-asserted-by":"crossref","unstructured":"Liu, G., Franssen, E., Fitch, M.I., & Warner, E. (1997). Patient preferences for oral versus intravenous palliative chemotherapy. <i>Journal of Clinical Oncology, 15<\/i>, 110-115.","DOI":"10.1200\/JCO.1997.15.1.110"},{"key":"E00024","doi-asserted-by":"crossref","unstructured":"Minnema, M.C., Breitkreutz, I., Auwerda, J.J., van der Holt, B., Cremer, F.W., van Marion, A.M., et al. (2004). Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy [Letter]. <i>Leukemia, 18<\/i>, 2044-2046.","DOI":"10.1038\/sj.leu.2403533"},{"key":"E00025","doi-asserted-by":"crossref","unstructured":"Mitsiades, N., Mitsiades, C.S., Poulaki, V., Chauhan, D., Richardson, P.G., Hideshima, T., et al. (2002). Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications. <i>Blood, 99<\/i>, 4525-4530.","DOI":"10.1182\/blood.V99.12.4525"},{"key":"E00026","doi-asserted-by":"crossref","unstructured":"Munshi, N.C. (2004). Recent advances in the management of multiple myeloma. <i>Seminars in Hematology, 41<\/i>(2, Suppl. 4), 21-26.","DOI":"10.1053\/j.seminhematol.2004.03.002"},{"key":"E00027","unstructured":"Myeloma Trialists' Collaborative Group. (1998). Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. <i>Journal of Clinical Oncology, 16<\/i>, 3832-3842."},{"key":"E00028","unstructured":"National Comprehensive Cancer Network. (2006). Clinical practice guidelines: Myelodysplastic syndromes (version 3.2006). Retrieved May 22, 2006, from <a target=\"_blank\" href='http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/mds.pdf'>http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/mds.pdf<\/a>"},{"key":"E00029","doi-asserted-by":"crossref","unstructured":"Palumbo, A., Bertola, A., Falco, P., Rosato, R., Cavallo, F., Giaccone, L., et al. (2004). Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. <i>Hematology Journal, 5<\/i>, 318-324.","DOI":"10.1038\/sj.thj.6200403"},{"key":"E00030","unstructured":"Palumbo, A., Giaccone, L., Bertola, A., Pregno, P., Bringhen, S., Rus, C., et al. (2001). Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. <i>Haematologica, 86<\/i>, 399-403."},{"key":"E00031","doi-asserted-by":"crossref","unstructured":"Rajkumar, S.V., Blood, E., Vesole, D.H., Shepard, R., & Greipp, P.R. (2004). A randomised phase III trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma (E1A00): A trial coordinated by the Eastern Cooperative Oncology Group [Abstract 6508]. <i>Journal of Clinical Oncology, 22<\/i>(Suppl. 14S), 560s.","DOI":"10.1200\/jco.2004.22.14_suppl.6508"},{"key":"E00032","doi-asserted-by":"crossref","unstructured":"Rajkumar, S.V., Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Fonseca, R., Geyer, S.M., et al. (2003). Thalidomide as initial therapy for early-stage myeloma. <i>Leukemia, 17<\/i>, 775-779.","DOI":"10.1038\/sj.leu.2402866"},{"key":"E00033","doi-asserted-by":"crossref","unstructured":"Rajkumar, S.V., Hayman, S., Gertz, M.A., Dispenzieri, A., Lacy, M.Q., Greipp, P.R., et al. (2002). Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. <i>Journal of Clinical Oncology, 20<\/i>, 4319-4323.","DOI":"10.1200\/JCO.2002.02.116"},{"key":"E00034","doi-asserted-by":"crossref","unstructured":"Rajkumar, S.V., Hayman, S.R., Lacy, M.Q., Dispenzieri, A., Geyer, S.M., Kabat, B., et al. (2005). Combination therapy with lenalidomide plus dexamethasone (rev\/dex) for newly diagnosed myeloma. <i>Blood, 106<\/i>, 4050-4053.","DOI":"10.1182\/blood-2005-07-2817"},{"key":"E00035","doi-asserted-by":"crossref","unstructured":"Richardson, P., Schlossman, R., Jagannath, S., Alsina, M., Desikan, R., Blood, E., et al. (2004). Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: Results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. <i>Mayo Clinic Proceedings, 79<\/i>, 875-882.","DOI":"10.4065\/79.7.875"},{"key":"E00036","unstructured":"Richardson, P.G., Jagannath, S., Schlossman, R., Zeldenrust, S., Rajkumar, S.V., Alsina, M., et al. (2003). A multi-center, randomized, phase 2 study to evaluate the efficacy and safety of 2 CDC-5013 dose regimens when used alone or in combination with dexamethasone (dex) for the treatment of relapsed or refractory multiple myeloma (MM) [Abstract 825]. <i>Blood, 102<\/i>(Pt. 1), 235a."},{"key":"E00037","doi-asserted-by":"crossref","unstructured":"Richardson, P.G., Schlossman, R.L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., et al. (2002). Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. <i>Blood, 100<\/i>, 3063-3067.","DOI":"10.1182\/blood-2002-03-0996"},{"key":"E00038","doi-asserted-by":"crossref","unstructured":"Schutt, P., Ebeling, P., Buttkereit, U., Brandhorst, D., Opalka, B., Hoiczyk, M., et al. (2005). Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. <i>European Journal of Haematology, 74<\/i>, 40-46.","DOI":"10.1111\/j.1600-0609.2004.00349.x"},{"key":"E00039","unstructured":"Scios, Inc. (2005). Study of oral SCIO-469 in relapsed, refractory patients with multiple myeloma. Retrieved May 22, 2006, from <a target=\"_blank\" href='http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00087867'>http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00087867<\/a>"},{"key":"E00040","unstructured":"Scios, Inc. (2006). Extension study of the efficacy and safety of oral SCIO-469 in relapsed, refractory patients with multiple myeloma. Retrieved May 22, 2006, from <a target=\"_blank\" href='http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00095680'>http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00095680<\/a>"},{"key":"E00041","doi-asserted-by":"crossref","unstructured":"Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., et al. (1999). Antitumor activity of thalidomide in refractory multiple myeloma. <i>New England Journal of Medicine, 341<\/i>, 1565-1571.","DOI":"10.1056\/NEJM199911183412102"},{"key":"E00042","doi-asserted-by":"crossref","unstructured":"Tiplady, C.W., & Summerfield, G.P. (2000). Continuous low-dose dexamethasone in relapsed or refractory multiple myeloma. <i>British Journal of Haematology, 111<\/i>, 381.","DOI":"10.1046\/j.1365-2141.2000.02372.x"},{"key":"E00043","doi-asserted-by":"crossref","unstructured":"Tosi, P., Zamagni, E., Cellini, C., Plasmati, R., Cangini, D., Tacchetti, P., et al. (2005). Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. <i>European Journal of Haematology, 74<\/i>, 212-216.","DOI":"10.1111\/j.1600-0609.2004.00382.x"},{"key":"E00044","doi-asserted-by":"crossref","unstructured":"Weber, D., Rankin, K., Gavino, M., Delasalle, K., & Alexanian, R. (2003). Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. <i>Journal of Clinical Oncology, 21<\/i>, 16-19.","DOI":"10.1200\/JCO.2003.03.139"},{"key":"E00045","doi-asserted-by":"crossref","unstructured":"Zangari, M., Anaissie, E., Barlogie, B., Badros, A., Desikan, R., Gopal, A.V., et al. (2001). Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. <i>Blood, 98<\/i>, 1614-1615.","DOI":"10.1182\/blood.V98.5.1614"},{"key":"E00046","doi-asserted-by":"crossref","unstructured":"Zangari, M., Barlogie, B., Anaissie, E., Saghafifar, F., Eddlemon, P., Jacobson, J., et al. (2004). Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: Effects of prophylactic and therapeutic anticoagulation. <i>British Journal of Haematology, 126<\/i>, 715-721.","DOI":"10.1111\/j.1365-2141.2004.05078.x"},{"key":"E00047","unstructured":"Zangari, M., Tricot, G., Zeldis, J., Eddlemon, P., Saghafifar, F., & Barlogie, B. (2001). Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT) [Abstract 3226]. <i>Blood, 98<\/i>(Pt. 1), 775a."},{"key":"E00048","doi-asserted-by":"crossref","unstructured":"Zervas, K., Dimopoulos, M.A., Hatzicharissi, E., Anagnostopoulos, A., Papaioannou, M., Mitsouli, C., et al. (2004). Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): A phase II multicenter study. <i>Annals of Oncology, 15<\/i>, 134-138.","DOI":"10.1093\/annonc\/mdh026"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/0030M46H3M880016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:51:31Z","timestamp":1763754691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/10\/4\/advances-oral-therapy-treatment-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,1]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,8,1]]}},"alternative-id":["0030M46H3M880016"],"URL":"https:\/\/doi.org\/10.1188\/06.cjon.514-520","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2006,8,1]]}}}